Educational content on VJHemOnc is intended for healthcare professionals only. By visiting this website and accessing this information you confirm that you are a healthcare professional.

Share this video  

EHA 2017 | Immune checkpoint inhibitors: shaping the future of lymphoma

Stephen Ansell • 22 Jun 2017
EHA 2017
Hodgkin Lymphoma Checkpoint inhibitors

Stephen Ansell, MD, PhD, from the Mayo Clinic, Rochester, MN, USA, briefly describes the effectiveness and recent approval of immune checkpoint therapies in treating lymphoma for patients in the US and in Europe, noting that this new form of therapy will be accessible to patients in the distant future. This interview was filmed at the European Hematology Association (EHA) 2017 Annual Congress in Madrid, Spain.

More from Stephen Ansell

Evolving frontline strategies to reduce relapse in DLBCL
1:43
Evolving frontline strategies to reduce relapse in DLBCL
Stephen Ansell • 11 Sep 2026
Selecting frontline therapy with BV-AVD or nivolumab plus AVD in Hodgkin lymphoma
1:16
Selecting frontline therapy with BV-AVD or nivolumab plus AVD in Hodgkin lymphoma
Stephen Ansell • 11 Sep 2026
Balancing efficacy and long-term toxicity in frontline Hodgkin lymphoma
1:10
Balancing efficacy and long-term toxicity in frontline Hodgkin lymphoma
Stephen Ansell • 11 Sep 2026
Combining brentuximab vedotin and nivolumab in Hodgkin lymphoma: advice & clinical considerations
1:19
Combining brentuximab vedotin and nivolumab in Hodgkin lymphoma: advice & clinical considerations
Stephen Ansell • 12 Jun 2026

Related Videos

Selecting frontline therapy with BV-AVD or nivolumab plus AVD in Hodgkin lymphoma
1:16
Selecting frontline therapy with BV-AVD or nivolumab plus AVD in Hodgkin lymphoma
Stephen Ansell • 11 Sep 2026
Balancing efficacy and long-term toxicity in frontline Hodgkin lymphoma
1:10
Balancing efficacy and long-term toxicity in frontline Hodgkin lymphoma
Stephen Ansell • 11 Sep 2026
Advice for community oncologists on managing patients with HL: when to refer to a specialist center
1:42
Advice for community oncologists on managing patients with HL: when to refer to a specialist center
Cathy Burton • 6 Jul 2026
UK insights into how brentuximab vedotin and PD-1 inhibitors are currently sequenced for relapsed HL
2:36
UK insights into how brentuximab vedotin and PD-1 inhibitors are currently sequenced for relapsed HL
Cathy Burton • 14 Jun 2026

Choose your cookie settings

VJHemOnc uses necessary cookies to make the site work. With your permission we'd also like to use analytics, preference and marketing cookies to understand how the site is used and improve it.

Choose an option to continue. You can change it at any time on our Cookie Policy page, linked at the bottom of every page.

Cookie Policy (opens in a new tab)
The content of VJHemOnc is intended for healthcare professionals